Besides low interest rates, a reduction in active Covid cases and strong high-frequency macro data have lifted the sentiment of both corporate India and the stock markets.
'Safety is my first priority.' 'I need to ensure that any drug or vaccine that our citizens get is first safe.'
The Covishield maker's forte throughout the past half a century has been a combination of affordable vaccines and high volumes. Its tetanus, diphtheria and measles vaccines are known throughout the world, reports Sohini Das.
Warehousing and logistics segment has been among the most resilient asset classes in the pandemic.
'We are hoping by March, the government allows us to export and give it to the private market.'
Although residential sales faced a major set back in Q2, they made a comeback with help of pent up demand.
'The government should put the whole road map together for the vaccine and decide how industry can support...' 'They should allow the private sector to vaccinate.'
The expert committee sought more information from Serum Institute regarding the Oxford-AstraZeneca vaccine.
The primary objective was to get the adult vaccine as children rarely have a severe form of the disease. Once schools reopen, the demand for vaccines for children under 12 may soar.
Each of the larger states may need less than Rs 10,000 crore each to finance the exercise.
For the AI bid, Interups has joined hands with a few employees of the airline, and plans to raise funds by splitting some of its infrastructure-related assets into an aviation InvIT, which will have underlying assets such as air routes, ground handling, repairs, and training etc.
At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield.
The vaccine would be first made available to the vulnerable population and eventually, it would be available in the private market for all.
Bharat Biotech is in the middle of conducting a phase 3 trial with 22,000 subjects.
A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.
India's first mRNA platform-based vaccine will remain stable at 2-8 degrees Celsius while Pfizer-BioNTech's vaccine needs minus 70 degrees Celsius and Moderna vaccine can remain stable for six months at minus 20 degrees Celsius, reports Sohini Das.
'Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,' says the volunteer's advocate.
The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.
By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.
From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies - Indian drug makers have shown that medicine sales is certainly a sunshine sector.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances